Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

NCT03358472 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Epacadostat
DRUG: Cetuximab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: 5-Fluorouracil

Sponsor

Incyte Corporation

Collaborators

[object Object]